CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,089 enrolled
Drug / intervention
semaglutide +1 moredrug
Likely dose
semaglutide 0.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02128932
NCT02128932Phase 3Completed
CompareCT.gov

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

Novo Nordisk A/S·interventional·Posted May 1, 2014·Updated Jun 13, 2019

In Brief

A Phase 3 clinical trial evaluating semaglutide and insulin glargine for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 1,089 participants across 231 sites in 15 countries.

Detailed Summary

This trial is conducted in Africa, North and South America, Asia and Europe. The purpose of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus insulin glargine once-daily on glycaemic control after 30 weeks of treatment in insulin-naïve subjects with type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesArgentina, Croatia, France, Germany, India, Mexico, Netherlands, North Macedonia, Puerto Rico, Romania, Slovakia, Slovenia, South Africa, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 1, 2014
Enrollment StartAug 4, 2014
Primary CompletionSep 3, 2015
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.2 years ago

Interventions

semaglutidedrug

Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.

insulin glarginedrug

Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.